Synergy Pharmaceuticals (SGYP) Receives ‘Analyst’ Rating

Synergy Pharmaceuticals (SGYP) : 2 analysts are covering Synergy Pharmaceuticals (SGYP) and their average rating on the stock is 1, which is read as a Strong Buy. 2 equity analysts believe that the stock has a bright future and the price doesnt capture all of its upside, hence they rate the stock as a Strong Buy. A Zacks Investment Research rank of 3, which recommends a Hold affirms that they expect a large upside in the stock from the current levels.

Synergy Pharmaceuticals (SGYP) : The highest level Synergy Pharmaceuticals (SGYP) is projected to reach is $15 for the short term and the lowest estimate is at $7. The consolidated price target from 2 rating analysts who initiate coverage on the stock is $10.75 and the possibility the share price can swing is $6.01.


Synergy Pharmaceuticals (NASDAQ:SGYP): After opening at $5.31, the stock dipped to an intraday low of $5.27 on Thursday. However, the bulls stepped in to buy at lower levels and pushed the stock higher. The stock touched an intraday high of $5.97 and the buying power remained strong till the end. The stock closed at $5.83 for the day, a gain of 10.00% for the day session. The total traded volume was 10,656,285. The stocks close on the previous trading day was $5.3.

Synergy Pharmaceuticals Inc. (Synergy) is a biopharmaceutical company focused on the development of drugs to treat gastrointestinal (GI), disorders and diseases. The Companys platform technology is based on the naturally occurring human GI peptide, uroguanylin, a regulator of normal GI physiology. The Companys products include plecanatide, SP-333 and FV-100. The Companys lead product is plecanatide, a guanylate cyclase C (GC-C), receptor agonist, designed to treat GI disorders, primarily chronic idiopathic constipation (CIC), and constipation predominant irritable bowel syndrome (IBS-C). The Company is developing a second-generation GC-C receptor agonist, SP-333, for the treatment of opioid induced constipation (OIC), and for inflammatory bowel disease (IBD). FV-100 is an orally available nucleoside analog. The Companys subsidiaries include Synergy Advanced Pharmaceuticals, Inc., IgX, Ltd and ContraVir Pharmaceuticals, Inc.

Leave a Reply

Get Pre-Market Alerts!

Get Pre-Market Analysts' Upgrades, Downgrades, Earnings & Initiations with our FREE daily email newsletter.